Anti-oxidative and anti-inflammatory effects of GLP-1 RAs and SGLT2i: the key for cardiorenal protection?

Type 2 diabetes mellitus (T2DM) is a prevalent and increasingly common chronic condition characterized by insulin resistance and hyperglycemia. It is associated with severe complications, particularly affecting cardiovascular and renal health. To address these challenges, two novel classes of medications, sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs), have been developed. Recent studies highlight these drugs' roles, not only in regulating blood sugar levels but also in conferring cardiovascular and renal protection. These protective effects appear to extend beyond basic glycemic control, implicating mechanisms such as the reduction of inflammation and oxidative stress, especially in critical organs like the heart and kidneys. Despite promising evidence, the intricacies of these mechanisms remain inadequately explored, warranting more focused research.This Research Topic aims to unravel the molecular bases by which SGLT2 inhibitors and GLP-1 receptor agonists exert their cardiorenal benefits in the context of T2DM. More specifically, it seeks to investigate the antioxidant and anti-inflammatory pathways implicated in these actions. Understanding this intricate molecular interplay will help in developing targeted therapeutic strategies, potentially improving clinical outcomes for patients with T2DM who are at heightened risk for cardiovascular and renal complications.To gather further insights into the multifaceted roles of SGLT2is and GLP-1RAs in T2DM beyond their glycemic effects, we welcome articles addressing, but not limited to, the following themes:- Mechanisms of action of SGLT2is and GLP-1RAs in promoting cardiovascular health.- Exploration of antioxidant pathways activated by these drug classes.- The role of inflammation attenuation in their protective effects.- Comparative studies on the efficacy of SGLT2is and GLP-1RAs.- Clinical implications and future directions for using these agents in T2DM management.We encourage the submission of various article types, including reviews, original research, and perspectives, to facilitate a comprehensive understanding of this evolving field. Topic editors: Susanna Longo, Michishige Terasaki Source: https://www.frontiersin.org/research-topics/81830/anti-oxidative-and-anti-inflammatory-effects-of-glp-1-ras-and-sglt2i-the-key-for-cardiorenal-protection